Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled Analysis

ABSTRACT Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. By releasing blocks (checkpoints) on the immune system, they elicit powerful antitumor effects. Despite improving survival, ICIs are associated with serious cardiac toxicities. Previous reports have focused...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Asma Dilawari, Mori J. Krantz, Ilynn Bulatao, Hee‐Koung Joeng, Marc Neilson, Suparna Wedam, Xin Gao, Mallorie H. Fiero, Abhilasha Nair, Marc Theoret, Laleh Amiri‐Kordestani
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Wiley 2025-05-01
Sarja:	Annals of Noninvasive Electrocardiology
Aiheet:	adjuvant cancer cardio oncology cardiotoxicity immune checkpoint inhibitors immunotherapy
Linkit:	https://doi.org/10.1111/anec.70087
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!